SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant attention as investors anticipate a major shift in institutional demand driven by the upcoming Russell Index reconstitution, which necessitates mandatory buying from passive funds. The community is actively tracking potential catalysts, including regulatory updates and revenue performance, while discussing how these factors might counteract persistent short-selling pressure.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors react to a newly announced multi-year joint research agreement with Honda, which validates the company's solid-state battery technology through rigorous benchmarking. The community is actively debating the significance of this OEM partnership, weighing the technical validation against the long-term timeline for commercial production.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently trending due to strong demand for its fuel cell solutions as AI data centers face urgent power grid constraints. The community is actively discussing the company's massive contract backlog and its emergence as a critical backbone for AI infrastructure.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing significant momentum driven by growing institutional interest and high expectations for upcoming Phase 3 trial data in non-small cell lung cancer (NSCLC) and the upcoming BLA filing. Community discourse is heavily focused on the stock's potential as a buyout target, with many participants viewing the current valuation as disconnected from the company's clinical progress and platform potential.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is surging as the memory sector benefits from critical supply constraints and strong AI data center demand, with market participants eagerly awaiting upcoming earnings reports for key sector leaders. The stock's parabolic climb has ignited intense community debate, with many investors highlighting massive long-term gains while skeptics warn of a potential bubble and increased volatility ahead of significant economic events.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum (HQ) is gaining significant traction as traders focus on its low float and strategic backing from major players like IonQ and Dell, positioning it as a potential "picks and shovels" play in the quantum software sector. While sentiment is divided between those anticipating a rapid short squeeze and skeptics raising concerns about limited patents and long-term valuation, the community is actively debating its potential as a specialized software-layer firm compared to other hardware-focused companies.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is generating significant market interest following a series of technical breakthroughs, including FDA clearance for an AI-powered gestational age tool and expanded government cloud authorizations. While community sentiment is divided between long-term investors tracking institutional backing and technical advancements, and traders wary of profit-taking pullbacks, the stock is trending as participants monitor its potential as an AI-driven platform play in the medical technology sector.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors aggressively build positions ahead of its upcoming Nasdaq-100 inclusion, driving the stock to fresh all-time highs amidst broad institutional interest in AI infrastructure. Community sentiment remains highly polarized, with intense debates between bulls betting on a structural breakout and bears arguing that the valuation has become decoupled from fundamental financial performance.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are trending as investors focus on positive FDA briefing documents and progress for its mRNA-1010 flu vaccine candidate ahead of an upcoming advisory committee meeting. The community is actively discussing the stock's long-term pipeline potential, including cancer vaccines, while debating current market sentiment and the stock's recent volatility.

Arqit Quantum, Inc. engages in the provision of cybersecurity services via satellite and terrestrial forms. Its product is QuantumCloud which secures devices with cloud-based quantum encryption. The company was founded by David John Williams and David James Bestwick on April 26, 2021 and is headquartered in London, the United Kingdom.

Arqit Quantum Inc

Arqit Quantum is experiencing high volatility and retail interest driven by its position in the post-quantum cybersecurity sector, fueled by speculative short squeeze narratives and active discussion of its low float. The community remains polarized, with some traders targeting technical breakouts and accumulation, while others express concerns over fundamental performance and the firm's history of heavy dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the companys proprietary Targeted RNAi Molecule (TRiM) platform. Each webinar in the...

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global Healthcare Conference June 2-4, 2026 Type: Fireside Chat Presentation Date/Time: June 3, 2026, 8:10 am EDT Goldman Sachs 47th Annual Global...

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the companys investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis...

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented new positive clinical data for plozasiran supporting its use in patients with moderate-to-severe renal impairment or moderate hepatic impairment without the need for dose adjustment, and a case report suggesting that preconception...

Wall Street's Cardiac Bet: Where Diagnostics Meet the Money

Wall Street's Cardiac Bet: Where Diagnostics Meet the Money Wall Street's Cardiac Bet: Where Diagnostics Meet the Money PR Newswire VANCOUVER, BC, May 12, 2026 ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News CommentaryVANCOUVER, BC, May 12, 2026 /PRNewswire/ --Cardiovascular...

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026...

Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained

SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.

Strs Ohio Has $2.09 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Strs Ohio grew its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 205.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 12-Month High  - Time to Buy?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week High - Should You Buy...

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowheads clinical stage RNA...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

ARWR Rallies 7% This Week As Europe Edges Closer To Redemplo Approval Amid Analyst Optimism

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

ARWRArrowhead Pharmaceuticals Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARWR News